人咽鳞癌细胞FaDu

细胞名称

人咽鳞癌细胞FaDu

货物编码

BFN60810331

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研   3类

培养体系

90%DMEM+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人咽鳞癌细胞FaDu取自56岁男性供体，贴壁培养。

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Doubling time: ~30 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced (low read coverage).

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突变

Homozygous for CDKN2A c.151-1G>T; splice acceptor mutation (ATCC).

Heterozygous for TP53 p.Arg248Leu (c.743G>T) (ClinVar=VCV000230253) and c.376-1G>A (p.Tyr126_Lys132del; c.376_396del21); splice acceptor mutation (PubMed=1394225; PubMed=11799138; PubMed=23613873; ATCC).

HLA信息

/

STR信息

Amelogenin        Not_detected (ATCC; CCRID; Cosmic-CLP; DSMZ; PubMed=21868764; PubMed=25877200)

X (KCLB)

CSF1PO        12

D2S1338        19

D3S1358        17,18

D5S818        12

D7S820        11,12

D8S1179        13

D13S317        8,9

D16S539        11 (ATCC; CCRID; Cosmic-CLP; PubMed=21868764; PubMed=25877200)

11,12 (DSMZ)

D18S51        16

D19S433        14,16

D21S11        31.2

FGA        25

Penta D        11

Penta E        17,19

TH01        8

TPOX        11

vWA        15,17,18 (ATCC; DSMZ)

15,17 (CCRID; Cosmic-CLP; KCLB; PubMed=21868764; PubMed=25877200)

参考文献

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004

van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I., Rene Leemans C., Wolthuis R.M.F., Brakenhoff R.H.

Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.

Oral Oncol. 98:53-61(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402.e16(2020)